<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）预计将在 2026 年 2 月 5 日星期四市场开盘前发布其 2026 年第三季度财报。分析师预计该公司将宣布每股收益为 1.16 美元，季度收入为 2.86932 亿美元。Prestige Consumer Healthcare 已将其 2026 财年的每股收益指导目标设定为 4.540-4.580。鼓励个人访问该公司即将发布的 2026 年第三季度财报概览页面，以获取有关定于 2026 年 2 月 5 日东部时间上午 8:30 的电话会议的最新信息。</p>
<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）最近于 11 月 6 日星期四发布了其财报。该公司报告季度每股收益为 1.07 美元，超出市场共识预期的 0.97 美元，超出幅度为 0.10 美元。Prestige Consumer Healthcare 的净利润率为 18.09%，股本回报率为 12.43%。该公司季度收入为 2.7411 亿美元，而分析师预期为 2.5714 亿美元。去年同期，该公司每股收益为 1.09 美元。与去年同期相比，该公司的季度收入下降了 3.4%。分析师平均预计 Prestige Consumer Healthcare 在当前财年将发布每股收益 5 美元，下一财年也将发布每股收益 5 美元。</p>
<h2>Prestige Consumer Healthcare 股票表现</h2>
<p>Prestige Consumer Healthcare 的股票在星期四开盘价为 63.18 美元。该公司的 50 日移动平均线为 62.32 美元，200 日移动平均线为 64.48 美元。Prestige Consumer Healthcare 的 1 年最低价为 57.25 美元，1 年最高价为 90.04 美元。该公司的流动比率为 3.70，速动比率为 2.51，债务与股本比率为 0.55。该公司的市值为 30.4 亿美元，市盈率为 15.68，市盈增长比率为 2.01，贝塔值为 0.40。</p>
<h2>Prestige Consumer Healthcare 内部活动</h2>
<p>在其他新闻中，副总裁 Jeffrey Zerillo 于 11 月 28 日星期五出售了 719 股公司的股票。股票以平均价格 60.00 美元出售，总价值为 43,140.00 美元。交易完成后，该副总裁持有公司股票 42,329 股，价值 2,539,740 美元。这代表其持股比例下降了 1.67%。该交易已在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过此超链接获取。内部人士持有公司股票的 1.40%。</p>
<h2>机构投资者对 Prestige Consumer Healthcare 的看法</h2>
<p>机构投资者最近增加或减少了对该公司的持股。AQR Capital Management LLC 在第一季度将其在 Prestige Consumer Healthcare 的股份增加了 11.9%。AQR Capital Management LLC 目前持有 30,056 股公司股票，价值 2,558,000 美元，此前在上个季度又收购了 3,200 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增加了对 Prestige Consumer Healthcare 的持股 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 29,490 股公司股票，价值 2,535,000 美元，此前在该期间又购买了 1,289 股。高盛集团在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 28.4%。高盛集团目前持有 546,672 股公司股票，价值 46,997,000 美元，此前在上个季度又购买了 120,965 股。Jane Street Group LLC 在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 204.0%。Jane Street Group LLC 目前持有 104,802 股公司股票，价值 9,010,000 美元，此前在上个季度又购买了 70,330 股。最后，Geneos Wealth Management Inc.在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 92.8%。Geneos Wealth Management Inc.目前持有 559 股公司股票，价值 48,000 美元，此前在该期间又购买了 269 股。99.95% 的股票由机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师对该公司进行了评估。Oppenheimer 在 10 月 21 日星期二的研究报告中将 Prestige Consumer Healthcare 的目标价格从 82.00 美元下调至 72.00 美元，并对该公司给予了 “跑赢大盘” 的评级。Zacks Research 在 11 月 10 日星期一的报告中将 Prestige Consumer Healthcare 的评级从 “强烈卖出” 上调至 “持有”。Jefferies Financial Group 在 10 月 27 日星期一的研究报告中将 Prestige Consumer Healthcare 的目标价格从 75.00 美元下调至 71.00 美元，并对该公司给予了 “持有” 评级。Canaccord Genuity Group 在 11 月 7 日星期五的研究报告中将 Prestige Consumer Healthcare 的目标价格从 100.00 美元下调至 88.00 美元，并对该股票给予了 “买入” 评级。最后，Weiss Ratings 在 1 月 22 日星期四的研究报告中重新发布了对 Prestige Consumer Healthcare 股票的 “持有（c）” 评级。四位分析师对该股票给予了买入评级，四位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，Prestige Consumer Healthcare 目前的平均评级为 “适度买入”，平均目标价格为 85.33 美元。</p>
<p><strong>查看我们对 Prestige Consumer Healthcare 的最新分析</strong></p>
<h2>关于 Prestige Consumer Healthcare</h2>
<p>（获取免费报告）</p>
<p>Prestige Consumer Healthcare, Inc 是一家领先的品牌非处方（OTC）医疗产品制造和营销公司。该公司专注于开发、收购和商业化多样化的非处方药物组合，以满足常见消费者健康需求，包括疼痛缓解、感冒和咳嗽、消化健康、眼部护理、皮肤护理和女性健康。</p>
<p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部护理）、Chloraseptic（喉咙痛缓解）、Dramamine（晕动病）、Rolaids（抗酸剂）、Monistat（女性健康）、BC Powder（疼痛缓解）、Little Remedies（儿童感冒和气体缓解）和 TheraTears（干眼治疗）。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而非 Prestige Consumer Healthcare</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤让您的银行账户 “防联储”</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地被激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资$1,000 到 Prestige Consumer Healthcare 吗？</h2>
<p>在您考虑 Prestige Consumer Healthcare 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Prestige Consumer Healthcare 并不在名单上。</p>
<p>虽然 Prestige Consumer Healthcare 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

普雷斯蒂奇

<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH）将于 2 月 5 日公布其 2026 年第三季度财报，预计每股收益为 1.16 美元，收入为 2.8693 亿美元。该公司此前报告的每股收益为 1.07 美元，超出预期。分析师预计 2026 财年的每股收益指导为 4.540-4.580。该股票开盘价为 63.18 美元，市值为 30.4 亿美元。最近的内部交易活动包括副总裁 Jeffrey Zerillo 出售股份，机构投资者已增加其持股。分析师的评级各不相同，目标价格范围在 71.00 美元至 88.00 美元之间</p>

<p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $1.16 per share and revenue of $286.9320 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Individuals are encouraged to explore the company's upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）预计将在 2026 年 2 月 5 日星期四市场开盘前发布其 2026 年第三季度财报。分析师预计该公司将宣布每股收益为 1.16 美元，季度收入为 2.86932 亿美元。Prestige Consumer Healthcare 已将其 2026 财年的每股收益指导目标设定为 4.540-4.580。鼓励个人访问该公司即将发布的 2026 年第三季度财报概览页面，以获取有关定于 2026 年 2 月 5 日东部时间上午 8:30 的电话会议的最新信息。</p>
</div><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The firm had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same period last year, the firm earned $1.09 EPS. The business's quarterly revenue was down 3.4% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）最近于 11 月 6 日星期四发布了其财报。该公司报告季度每股收益为 1.07 美元，超出市场共识预期的 0.97 美元，超出幅度为 0.10 美元。Prestige Consumer Healthcare 的净利润率为 18.09%，股本回报率为 12.43%。该公司季度收入为 2.7411 亿美元，而分析师预期为 2.5714 亿美元。去年同期，该公司每股收益为 1.09 美元。与去年同期相比，该公司的季度收入下降了 3.4%。分析师平均预计 Prestige Consumer Healthcare 在当前财年将发布每股收益 5 美元，下一财年也将发布每股收益 5 美元。</p>
</div><h2>Prestige Consumer Healthcare Stock Performance</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 股票表现</h2>
</div><p>Shares of Prestige Consumer Healthcare stock opened at $63.18 on Thursday. The company has a 50 day moving average of $62.32 and a 200-day moving average of $64.48. Prestige Consumer Healthcare has a 1-year low of $57.25 and a 1-year high of $90.04. The company has a current ratio of 3.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. The company has a market cap of $3.04 billion, a PE ratio of 15.68, a price-to-earnings-growth ratio of 2.01 and a beta of 0.40.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare 的股票在星期四开盘价为 63.18 美元。该公司的 50 日移动平均线为 62.32 美元，200 日移动平均线为 64.48 美元。Prestige Consumer Healthcare 的 1 年最低价为 57.25 美元，1 年最高价为 90.04 美元。该公司的流动比率为 3.70，速动比率为 2.51，债务与股本比率为 0.55。该公司的市值为 30.4 亿美元，市盈率为 15.68，市盈增长比率为 2.01，贝塔值为 0.40。</p>
</div><h2>Insider Activity at Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 内部活动</h2>
</div><p>In other news, VP Jeffrey Zerillo sold 719 shares of the company's stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares of the company's stock, valued at $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，副总裁 Jeffrey Zerillo 于 11 月 28 日星期五出售了 719 股公司的股票。股票以平均价格 60.00 美元出售，总价值为 43,140.00 美元。交易完成后，该副总裁持有公司股票 42,329 股，价值 2,539,740 美元。这代表其持股比例下降了 1.67%。该交易已在向美国证券交易委员会（SEC）提交的文件中披露，文件可通过此超链接获取。内部人士持有公司股票的 1.40%。</p>
</div><h2>Institutional Investors Weigh In On Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>机构投资者对 Prestige Consumer Healthcare 的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its stake in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock valued at $2,558,000 after acquiring an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Prestige Consumer Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock valued at $2,535,000 after purchasing an additional 1,289 shares during the period. Goldman Sachs Group Inc. raised its position in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Jane Street Group LLC raised its position in Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock worth $9,010,000 after purchasing an additional 70,330 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock worth $48,000 after buying an additional 269 shares during the period. 99.95% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该公司的持股。AQR Capital Management LLC 在第一季度将其在 Prestige Consumer Healthcare 的股份增加了 11.9%。AQR Capital Management LLC 目前持有 30,056 股公司股票，价值 2,558,000 美元，此前在上个季度又收购了 3,200 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增加了对 Prestige Consumer Healthcare 的持股 4.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 29,490 股公司股票，价值 2,535,000 美元，此前在该期间又购买了 1,289 股。高盛集团在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 28.4%。高盛集团目前持有 546,672 股公司股票，价值 46,997,000 美元，此前在上个季度又购买了 120,965 股。Jane Street Group LLC 在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 204.0%。Jane Street Group LLC 目前持有 104,802 股公司股票，价值 9,010,000 美元，此前在上个季度又购买了 70,330 股。最后，Geneos Wealth Management Inc.在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 92.8%。Geneos Wealth Management Inc.目前持有 559 股公司股票，价值 48,000 美元，此前在该期间又购买了 269 股。99.95% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have weighed in on the company. Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an &#34;outperform&#34; rating for the company in a research note on Tuesday, October 21st. Zacks Research raised Prestige Consumer Healthcare from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, November 10th. Jefferies Financial Group dropped their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a &#34;hold&#34; rating for the company in a research report on Monday, October 27th. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $85.33.</p>
<div class="lb-trans"><p>几位股票研究分析师对该公司进行了评估。Oppenheimer 在 10 月 21 日星期二的研究报告中将 Prestige Consumer Healthcare 的目标价格从 82.00 美元下调至 72.00 美元，并对该公司给予了 “跑赢大盘” 的评级。Zacks Research 在 11 月 10 日星期一的报告中将 Prestige Consumer Healthcare 的评级从 “强烈卖出” 上调至 “持有”。Jefferies Financial Group 在 10 月 27 日星期一的研究报告中将 Prestige Consumer Healthcare 的目标价格从 75.00 美元下调至 71.00 美元，并对该公司给予了 “持有” 评级。Canaccord Genuity Group 在 11 月 7 日星期五的研究报告中将 Prestige Consumer Healthcare 的目标价格从 100.00 美元下调至 88.00 美元，并对该股票给予了 “买入” 评级。最后，Weiss Ratings 在 1 月 22 日星期四的研究报告中重新发布了对 Prestige Consumer Healthcare 股票的 “持有（c）” 评级。四位分析师对该股票给予了买入评级，四位分析师对该公司给予了持有评级。根据 MarketBeat.com 的数据，Prestige Consumer Healthcare 目前的平均评级为 “适度买入”，平均目标价格为 85.33 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Prestige Consumer Healthcare</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Prestige Consumer Healthcare 的最新分析</strong></p>
</div><h2>About Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>关于 Prestige Consumer Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare, Inc 是一家领先的品牌非处方（OTC）医疗产品制造和营销公司。该公司专注于开发、收购和商业化多样化的非处方药物组合，以满足常见消费者健康需求，包括疼痛缓解、感冒和咳嗽、消化健康、眼部护理、皮肤护理和女性健康。</p>
</div><p>Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).</p>
<div class="lb-trans"><p>Prestige 的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部护理）、Chloraseptic（喉咙痛缓解）、Dramamine（晕动病）、Rolaids（抗酸剂）、Monistat（女性健康）、BC Powder（疼痛缓解）、Little Remedies（儿童感冒和气体缓解）和 TheraTears（干眼治疗）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Prestige Consumer Healthcare</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Prestige Consumer Healthcare</li>
<li>家族信托如何帮助保护您的财富</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤让您的银行账户 “防联储”</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地被激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&amp;Symbol=PBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资$1,000 到 Prestige Consumer Healthcare 吗？</h2>
</div><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Prestige Consumer Healthcare 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Prestige Consumer Healthcare 并不在名单上。</p>
</div><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prestige Consumer Healthcare 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

普雷斯蒂奇消费者医疗保健公司（PBH）预计将在周四公布季度财报